03.23.2019 Issue 164

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Jobs Round-up
Job of the Week Latest Jobs from the Jobs Portal

 Scientific Writer

Agile Outcomes Research is looking for an ambitious and entrepreneurially-minded Scientific Writer to contribute to Health Economics and Outcomes Research publications and presentations.

Senior Research Analyst (HEOR)

Medical Statistician

Health Economics & Real-World Evidence (HE-RWE) Scientist

Senior Health Economics & Real-World Evidence (HE-RWE) Scientist

Senior Health Economics/Outcomes Researcher

Senior Health Economist (HTA and Market Access)

Head of Economic Modelling

Director, Real World Value and Evidence, Oncology


ICER Releases Updated Protocol for Assessing Price Hikes

Article on Drug Prices Spurs Debate

Gottlieb Slams Sponsors Over Unwillingness to Rethink Trials

Legislators Target Anti-Competitive Practices

Industry Spotlight


Conferences Webinars
Drug Pricing Transparency Congress
    March 25-26, Philadelphia, Pennsylvania

Health Economics for Non-Health-Economists
    March 26-27, Brussels, Belgium

ISPOR Warsaw 2019
    March 27-28, Warsaw, Poland

Expanded Access Programs 2019
    March 27-28, Philadelphia, Pennsylvania

Using RWE to Improve Healthcare Decision-making in Asia Pacific
    March 25

The Use of MCDA for HTA Agencies – Options, Limitations, and the Way Forward
    April 3

MCDA - How to Guide Through the Application of Different Methods for Assessment and Prioritization of Rare Disease Health Technologies
    April 4


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Review of Influence: The Institute for Clinical and Economic Review

Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs and Biologics

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


Special Thanks to Our Partners:
                   Truven         
              Evidera    HealthCore    University of FL
      Xcenda    OM1    Parexel    Jefferson    Dymaxium    
      Precision Xtract    Pharmerit    eMax Health    Sciformix
       Evidence Partners     ICON